Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Short term Debt (2016 - 2023)

Ligand Pharmaceuticals (LGNDZ) has disclosed Short term Debt for 9 consecutive years, with $76.8 million as the latest value for Q1 2023.

  • Quarterly Short term Debt changed N/A to $76.8 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $76.8 million through Mar 2023, changed N/A year-over-year, with the annual reading at $76.7 million for FY2022, N/A changed from the prior year.
  • Short term Debt hit $76.8 million in Q1 2023 for Ligand Pharmaceuticals, roughly flat from $76.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $115.0 million in Q2 2022 to a low of $18.7 million in Q1 2019.
  • Historically, Short term Debt has averaged $65.1 million across 3 years, with a median of $76.6 million in 2022.
  • Biggest YoY gain for Short term Debt was 87.12% in 2019; the steepest drop was 91.77% in 2019.
  • Year by year, Short term Debt stood at $27.1 million in 2019, then soared by 183.14% to $76.7 million in 2022, then increased by 0.12% to $76.8 million in 2023.
  • Business Quant data shows Short term Debt for LGNDZ at $76.8 million in Q1 2023, $76.7 million in Q4 2022, and $76.6 million in Q3 2022.